Business Description
2cureX AB
ISIN : SE0010468124
Total Employee Number:
14Compare
Compare
Traded in other countries / regions
2CUREX.Sweden2QE.Germany IPO Date
2017-11-24Description
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.12 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 48.7 | |||||
3-Year EPS without NRI Growth Rate | 46 | |||||
3-Year FCF Growth Rate | 45.3 | |||||
3-Year Book Growth Rate | -64.8 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.55 | |||||
9-Day RSI | 47.03 | |||||
14-Day RSI | 48.85 | |||||
3-1 Month Momentum % | 58.64 | |||||
6-1 Month Momentum % | 38.41 | |||||
12-1 Month Momentum % | -36.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.14 | |||||
Quick Ratio | 1.14 | |||||
Cash Ratio | 1.12 | |||||
Days Sales Outstanding | 24739.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.8 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -24012 | |||||
Net Margin % | -20800 | |||||
EBITDA Margin % | -24012 | |||||
FCF Margin % | -7732 | |||||
OCF Margin % | -7732 | |||||
ROE % | -192.88 | |||||
ROA % | -78.28 | |||||
ROIC % | -151.88 | |||||
3-Year ROIIC % | -1074.34 | |||||
ROC (Joel Greenblatt) % | -987.34 | |||||
ROCE % | -222.66 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.55 | |||||
PS Ratio | 1872 | |||||
PB Ratio | 74.88 | |||||
Price-to-Tangible-Book | 62.4 | |||||
EV-to-EBIT | -6.98 | |||||
EV-to-EBITDA | -6.98 | |||||
EV-to-Revenue | 1675.8 | |||||
EV-to-Forward-Revenue | 10.19 | |||||
EV-to-FCF | -21.26 | |||||
| Price-to-Net-Current-Asset-Value | 93.6 | |||||
| Price-to-Net-Cash | 93.6 | |||||
Earnings Yield (Greenblatt) % | -14.32 | |||||
FCF Yield % | -4.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
2cureX AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.025 | ||
| EPS (TTM) (kr) | -0.88 | ||
| Beta | 2.638 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1.89 | ||
| Volatility % | 359.52 | ||
| 14-Day RSI | 48.85 | ||
| 14-Day ATR (kr) | 0.124083 | ||
| 20-Day SMA (kr) | 1.93 | ||
| 12-1 Month Momentum % | -36.96 | ||
| 52-Week Range (kr) | 0.514 - 4.2 | ||
| Shares Outstanding (Mil) | 25.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
2cureX AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
2cureX AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-27 | In 37 days | ||
| General meeting for 2026 | 2026-06-25 | 1.88 (+0.00%) | ||
| Annual report for 2025 | 2026-05-28 | 1.73 (-6.27%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 1.64 (+13.15%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 3.31 (-7.80%) | ||
| General meeting for 2025 | 2025-06-26 10:00 | 3.55 (-1.39%) | ||
| Annual report for 2024 | 2025-05-29 | 1.99 (-1.73%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-02-27 | 0.42 (+4.25%) | ||
| Fourth quarter earnings results for 2024 | 2025-02-27 | 0.42 (+4.25%) | ||
| Second quarter earnings results for 2024 | 2024-08-22 | 0.42 (+2.93%) |
Show
Entries
2cureX AB Frequently Asked Questions
What is 2cureX AB(OSTO:2CUREX)'s stock price today?
The current price of OSTO:2CUREX is kr1.87. The 52 week high of OSTO:2CUREX is kr4.20 and 52 week low is kr0.51.
When is next earnings date of 2cureX AB(OSTO:2CUREX)?
The next earnings date of 2cureX AB(OSTO:2CUREX) is 2026-08-27.
Does 2cureX AB(OSTO:2CUREX) pay dividends? If so, how much?
2cureX AB(OSTO:2CUREX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on 2cureX AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers